Clinical Study of Solifenacin Succinate in Patients With Bladder Sympt
A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Solifenacin
- solifenacin 5 mg tablet
Compared with
- Oxybutynin
Muscarinic acetylcholine receptor M2 antagonist|Muscarinic acetylcholine receptor M3 antagonist
Placebo
- Placebo
What it measured
Main measures
Change from baseline in maximum cystometric capacity
4 Weeks
Other measures (7)
Change from baseline in bladder volume at first involuntary contraction
4 Weeks
Bladder, bowel and sexual functionChange from baseline in pressure at first leak
4 Weeks
Change from baseline in volume at first leak
4 Weeks
Change from baseline in maximum detrusor pressure
4 Weeks
Change from baseline in micturition or catheterization frequency
4 Weeks
Change from baseline in incontinence episodes
4 Weeks
Bladder, bowel and sexual functionIncidence and severity of adverse events
4 Weeks
Safety
Who could take part
MS (type not specified) · 18 to 65
Show the full criteria
Inclusion criteria
* Written informed consent has been obtained * Subjects with neurogenic detrusor overactivity due to: * Multiple sclerosis(MS)(EDSS≤8) or * Spinal cord injury(SCI)(partial or complete lesions) * MS or SCI symptoms should be stable for >= 6 months * Neurogenic detrusor overactivity symptoms should be stable for >= 6 months * Subject is willing and able to perform clean, intermittent, catheterization, if required * Subject is willing and able to take study medication in compliance with the protocol
Exclusion criteria
* Subjects with neurogenic detrusor overactivity due to Parkinson's or cerebrovascular disease * Subjects with Sjögren's Syndrome or any similar symptoms * Subjects with evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs * Subjects with stress incontinence or mixed incontinence where stress is the predominant factor as determined by the investigator * Subjects with evidence of pressure sores >= grade 2 * Subjects with a history of bladder sphincterotomy * Subjects with known history of vesico-ureteral reflux without upper urinary tract infection * Any clinically significant condition, which in the opinion of the investigator makes the subject unsuitable for the study or includes a history of acute urinary retention, severe gastrointestinal obstruction (including paralytic ileus or intestinal atony), severe gastrointestinal conditions (including toxic megacolon or ulcerative colitis), myasthenia gravis, narrow angle glaucoma or shallow anterior chamber * Subjects undergoing hemodialysis * Subjects with severe hepatic impairment * Concurrent use of drugs intended to treat symptoms of overactive bladder * Use of antidepressants or muscle relaxants which have not been administered at a constant dose for >= 3 months * Use of non-drug treatment intended to treat overactive bladder symptoms including electrostimulation therapy, botulinum toxin and vanilloids therapy in the six months prior to the commencement of the study * Use of permanent, indwelling catheters * Known or suspected hypersensitivity to solifenacin succinate, oxybutynin hydrochloride, other anti cholinergics or lactose * Concomitant use of a strong CYP3A4 inhibitor, e.g. ketoconazole * Pregnant women, women who intend to become pregnant during the study, women of childbearing potential who are sexually active and practicing an unreliable method of birth control or women who will be lactating during the study. Reliable contraceptive methods are intra-uterine devices, contraceptive pills of combination type, hormonal implants and injectable contraceptives * Participation in any clinical study within 30 days of randomization, or the limit set by national law, whichever is longer * Employees of the Astellas Group, third parties associated with the study, or the study site * Subjects with maximum bladder capacity >= 400ml at visit 2
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
A clinical study to evaluate the efficacy and safety of solifenacin in patients with bladder symptoms due to spinal cord injury or multiple sclerosis
Papers
Loading reviews and guidelines…
Related trials
- Cryoneurolysis to treat pain in the context of spasticity
Phase 4 · Ongoing (inferred)
Still running
- Silodosin for Urinary Symptoms in Female Patients With Multiple Sclero
Phase 4 · Recruiting
Still running
- Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomati
Not a drug-phase study · Status unknown
No results found
- Antibiotic strategy and asymptomatic bacteriuria in the context of int
Phase 3 · Ongoing
Still running
- Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactiv
Phase 4 · Stopped early
Stopped
- Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neu
Phase 3 · Stopped early
Stopped
History
Started
Mar 2008
Main results due
Jan 2011
Finished
Jan 2011